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OP4. EFFECTIVENESS OF RITUXIMAB IN RHEUMATOID
ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR
RHEUMATOLOGY BIOLOGICS REGISTER (BSRBR)
Moetaza M. Soliman1, Darren M. Ashcroft1, Kath D. Watson2,
Mark Lunt2, Deborah Symmons2 and Kimme L. Hyrich2
1School of Pharmacy and Pharmaceutical Sciences, University of
Manchester, Manchester, United Kingdom; 2Arthritis Research UK
Epidemiology Unit, The University of Manchester, Manchester,
United Kingdom
Background: Rituximab (RTX) in combination with methotrexate
(MTX) has been licensed since 2006 for the management of severe
active rheumatoid arthritis (RA) in patients who have failed at least one
anti-tumour necrosis factor (anti-TNF) therapy. Published clinical trials
have demonstrated the efficacy of RTX in improving both clinical
symptoms and patients’ physical function. This study aimed to assess
the effectiveness of RTX in RA patients treated in routine clinical
practice by examining clinical and patient reported outcomes six
months after receiving a first course of RTX.
Methods: The analysis involved 550 RA patients registered with
the BSRBR, who were starting RTX and were followed up for at
least 6 months. Change in Disease Activity Score (DAS28) and
European League Against Rheumatism (EULAR) response were used
to assess the clinical response while change in Health Assessment
Questionnaire (HAQ) score was used to assess the physical function of
the patients 6 months after starting RTX. The change in DAS28 and
HAQ was compared between seronegative and seropositive patients
and anti-TNF naı¨ve patients versus anti-TNF failures. The response
was also compared between patients receiving RTX in combination
with MTX, other non-biologic disease modifying anti-rheumatic drugs
(nbDMARDs) or no nbDMARDs.
Results: The mean (S.D.) age of the cohort was 59 (12) years and 78%
of the patients were females. The patients had a mean (S.D.) of 15 (10)
years of disease duration. 16% were biologic naı¨ve while 84% were
anti-TNF failures. 32% of the patients were seronegative and 68%
were seropositive. The mean (95% CI) DAS28 at baseline was 6.2 (6.1,
6.3) which decreased to 4.8 (4.7, 4.9) at 6 months of follow up. 16%
were EULAR good responders, 43% were moderate responders and
41% were non responders. The mean (95% CI) change in HAQ was
0.1 (0.2, 0.1) (Table 1). The mean change in DAS28 was similar in
seropositive and seronegative patients (p¼ 0.18) while the anti-TNF
naı¨ve patients showed a greater reduction in DAS28 scores than anti-
TNF failures (p¼ 0.05). Patients receiving RTX in combination with
MTX showed similar changes in DAS28 and HAQ compared to
patients receiving RTX alone or with other nbDMARDs.
Conclusions: RTX has proven to be effective in the routine clinical
practice. Anti-TNF naı¨ve patients seem to benefit more from RTX
treatment than anti-TNF failures.
Disclosure statement: The authors have declared no conflicts of
interest.
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Background: Canakinumab provides sustained interleukin-1b (IL-1b)
blockade and is effective in the treatment of cryopyrin-associated
periodic syndrome (CAPS), comprising familial cold auto-inflammatory
syndrome [FCAS], Muckle-Wells syndrome [MWS], neonatal-onset
multisystem inflammatory disease/chronic infantile neurologic, cuta-
neous and articular syndrome [NOMID/CINCA]. Herein we report the
long-term safety, tolerability, and efficacy of canakinumab in paediatric
CAPS patients from the largest study across all CAPS phenotypes
conducted to date.
Methods: Canakinumab-naı¨ve or roll-over patients from earlier studies
received canakinumab s.c. 150 mg or 2 mg/kg (40 kg) every 8 weeks
for up to 2 years. Complete response was assessed for canakinumab-
naı¨ve patients at Day 8 and in case of residual symptoms patients
could be maintained on a more intense dosing regimen (increase dose
up to 600 mg s.c. or 8 mg/kg s.c. [40 kg] and/or increase of dosing
frequency). Complete response was defined as physician’s global
assessment of disease activity (PGDA) and skin assessment
scoreminimal and normal CRP and/or SAA values (<10 mg/L).
Relapse was defined for patients with prior complete response as
serum levels of CRP and/or SAA >30 mg/L and PGDA >minimal or
PGDA¼minimal plus skin assessment >minimal.
TABLE 1.
Outcomes Entire
cohort
(n¼ 550)
Anti-TNF
naı¨ve
(n¼ 87)
Anti-TNF
failures
(n¼ 463)
P valuea Sero-
positive
(n¼373)
Sero-
negative
(n¼ 177)
P valueb RTXþMTX
(n¼ 286)
RTX mono-
therapy
(n¼ 125)
RTXþOther
DMARDs
(n¼ 138)
P valuec
Mean change in
DAS28 (95% CI)
1.4
(1.5, 1.3)
1.7
(2.0, 1.4)
1.3
(1.5, 1.2)
0.05* 1.4
(1.6, 1.3)
1.2
(1.4, 1.0)
0.18* 1.4
(1.6, 1.2)
1.5
(1.7, 1.2)
1.3
(1.6, 1.0)
0.62y
EULAR response, n (%)
Good 90 (16) 19 (22) 71 (15) 0.06z 65 (17) 25 (14) 0.30z 48 (17) 17 (14) 25 (18) 0.78z
Moderate 236 (43) 42 (48) 194 (42) 164 (44) 72 (41) 124 (43) 57 (45) 54 (39)
None 224 (41) 26 (30) 198 (43) 144 (39) 80 (45) 114 (40) 51 (41) 59 (43)
Mean change in
HAQ (95% CI)
0.1
(0.2, 0.1)
0.2
(0.2, 0.1)
0.1
(0.2, 0.1)
0.32* 0.1
(0.2, 0.1)
0.1
(0.2, 0.0)
0.78* 0.1
(0.2, 0.1)
0.1
(0.2, 0.1)
0.1
(0.2, 0.0)
0.90y
atest of significance between anti-TNF failures and anti-TNF naı¨ve patients, bbetween sero-negative and positive patients, camong patients with different concurrent
nbDMARDs. *Two independent samples t-test, yOne-way analysis of variance, zPearson Chi square test
Results: Of 47 paediatric (3-17 years) patients (1 patient did not have
CAPS and was discontinued [protocol violation] and of the remaining
46 patients there were 5 FCAS, 23 MWS, 18 MWS/NOMID [includes 8
NOMID/CINCA] patients), 38 were canakinumab-naı¨ve, while 9 had
been pre-treated with canakinumab. The study was completed by 43
(91%) patients and 3 patients discontinued the study (1 due to adverse
event [AE]). The median duration of exposure to study drug was 290
days (range: 29-625 days). Complete response was achieved in most
(68%, n¼26) of canakinumab-naı¨ve paediatric patients. The majority
of canakinumab-treated paediatric patients were relapse-free (83%
[29 out of 35 patients who were included in the relapse assessment])
and 6 patients experienced a relapse. Dosing adjustments were
required in 17(36%) patients. In canakinumab-naı¨ve patients median
CRP and SAA levels rapidly decreased within 7 days (2.5 and 7.4 mg/L
[baseline levels were 16.5 and 53.5 mg/L, respectively]) and these
levels were maintained at normal levels (<10 mg/L) during the study
(both in naı¨ve and roll-over patients). The most frequent AEs were
rhinitis, nasopharyngitis and headache. Serious AEs were reported in 6
paediatric patients. Most patients (n¼ 43, 91%) had no injection site
reactions.
Conclusions: Canakinumab s.c. every 8 weeks induced rapid and
sustained clinical and biochemical remission in paediatric patients
across all severity phenotypes of CAPS. Adjustment of dosing regimen
is an effective approach in paediatric CAPS patients to achieve
disease control. Canakinumab showed favorable long-term tolerability
and safety profile.
Disclosure statement: R.C. is/has been a member of speakers’
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and has received consultancy fees from Novartis Pharmaceuticals
Corporation. I.F., E.H., P.H. and I.K. have received consultancy fees
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Corporation. E.I. and G.K. are shareholders and employees of
Novartis Pharma AG. J.K. has received a research grant and
consultancy fee from Novartis Pharmaceuticals Corporation. H.L.
has received a research grant from the EU framework and a
consultancy fee from Novartis Pharmaceuticals Corporation. R.P. is
a shareholder and employee of Novartis Pharmaceuticals Corporation.
P.Q. has received a research grant and consultancy fee from Novartis
Pharmaceuticals Corporation. All other authors have declared no
conflicts of interest.
OP6. CANAKINUMAB (ACZ885) RELIEVES PAIN AND
CONTROLS INFLAMMATION RAPIDLY IN PATIENTS WITH
DIFFICULT-TO-TREAT GOUTY ARTHRITIS: COMPARISON
WITH TRIAMCINOLONE ACETONIDE
Alexander So1, M. De Meulemeester2, A. Pikhlak3, A. E. Yu¨cel4,
B. Bodalia5, J. Kerrane6, U. Arulmani7, D. Richard7, V. Murphy7,
P. Sallstig7 and N. Schlesinger8
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Care, Novartis Pharma AG, Basel, Switzerland; 8UMDNJ, Robert
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Background: Monosodium urate (MSU) crystals stimulate the pro-
duction of interleukin-1b (IL-1b), a potent inflammatory cytokine.
Targeted IL-1b blockade with canakinumab, a fully human monoclonal
anti-IL-1b antibody, is a novel treatment for gouty arthritis. Its effects
on pain and inflammation in acute gouty arthritis flares were compared
with triamcinolone acetonide (TA). TA has been shown to be effective
in the treatment of acute gouty arthritis flares.
Methods: This was an 8-week, dose-ranging, multicenter, blinded,
active-controlled trial. Patients 18 to 80 years with an acute gouty
arthritis flare, refractory to or contraindicated to NSAIDs and/or
colchicine were randomized to one subcutaneous dose of canakinu-
mab (10, 25, 50, 90, or 150 mg; n¼ 143) or one intramuscular dose of
TA (40 mg; n¼57). Primary outcome was pain intensity at 72 hours
post dose on VAS scale (0-100 mm). Secondary outcomes included C-
reactive protein (CRP), serum amyloid A (SAA), and physician’s
assessment of tenderness, swelling and erythema of target joint at
72 hours, 7 days, 4 and 8-weeks post dose.
Results: 191/200 patients completed the study. Canakinumab
showed a statistically significant dose response at 72 hours. The
150 mg dose group reached superior pain relief compared to TA group
starting from 24 hours as previously reported. At 72 hours post dose,
78% of canakinumab 150 mg treated patients achieved 75% and
96% achieved 50% reduction in pain from baseline. In contrast, 45%
and 61% of patients treated with TA achieved 75% and 50% pain
reduction, respectively. Median CRP/SAA levels were normalized by
Day 7 for all canakinumab doses above 10 mg and remained below the
upper limit of normal [(ULN): CRP 3.0 mg/L; SAA 6.7 mg/L)] for rest of
the study. In TA group, median CRP levels remained above the ULN
throughout the study while median SAA levels decreased below ULN
only 28 days after first dose. At 72 hours post dose, canakinumab
150 mg group was 3.2 (95% CI, 1.27-7.89) times more likely to have
less joint tenderness and 2.7 (95% CI, 1.09-6.5) times more likely to
have less joint swelling than TA group (p< 0.05). At 72 hours post
dose, erythema disappeared in 74.1% of patients receiving canakinu-
mab 150 mg and 69.6% of patients receiving TA. At 7 days post dose,
erythema was absent in 96.3% of canakinumab 150 mg treated
patients vs. 83.9% of patients receiving TA. The overall incidence of
AEs was similar for canakinumab (41%) and triamcinolone acetonide
(42%). Serious AEs (canakinumab treatment groups n¼ 4, TA n¼1)
were not considered treatment-related by investigators. No discon-
tinuations due to AEs occurred.
Conclusions: Canakinumab 150 mg provided superior pain relief
compared to TA for acute flares in difficult-to-treat gouty arthritis
patients. Canakinumab provided rapid normalization of markers of
inflammation accompanied by reduction of clinical signs and symp-
toms of inflammation.
Disclosure statement: U.A., V.M., D.R. and P.S. are shareholders and
employees of Novartis Pharma AG. A.P. has received research support
from Novartis Pharma AG. N.S. has received research support from
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bureau for Takeda. A.S. has received consultancy fees from Novartis
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Bristol-Myers Squibb. All other authors have declared no conflicts of
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OP7. SUCCESSFUL USE OF IL-6 BLOCKADE WITH
TOCILIZUMAB IN LARGE VESSEL GIANT CELL ARTERITIS
OF POLYMYALGIC ONSET
Dimitrios Christidis1, Nada Hassan1, Sarah Mapplebeck1 and
Bhaskar Dasgupta1
1Rheumatology, Southend University Hospital, Westcliff-On-Sea,
United Kingdom
Background: Interleukin-6 has been found to be significantly elevated
in patients with both Polymyalgia rheumatica (PMR) and Giant cell
arteritis (GCA). Serum IL6 was identified in several studies as a marker
of relapse and recurrence of the disease with studies revealing over-
expression of IL-6 messenger RNA in temporal artery biopsies (TAB).
This may explain the systemic inflammatory response seen in these
diseases.
The main stay of treatment of GCA and PMR is steroid therapy.
Steroid sparing strategies with methotrexate and azathioprine are
currently recommended in resistant cases. Anti TNF therapy with
etanercept, infliximab or adalumimab is not of therapeutic benefit.
There is one reported case in the literature on the use of Tocilizumab
(TCZ) in a patient with resistant PMR with an excellent outcome.
Large vessel involvement of the aorta and major blood vessels is a
well recognised complication of both GCA and PMR. We report the
successful use of TCZ in such a case.
Methods: A 63-year-old female, diagnosed with PMR in 2003, on
continuous steroids, presented with a 12 week history of worsening
proximal pain and stiffness. She was given steroid sparing agents on
different occasions including methotrexate, leflunomide and azathiopr-
ine, with no benefit and was unable to wean-off her steroids.
In August 2010 her symptoms worsened with new onset headache,
fatigue, loss of appetite and weight and transient visual loss. TAB
showed granulomatous inflammation and intimal hyperplasia and an
ultrasound showed the typical ‘Halo’ sign in both temporal as well as
axillary arteries. FDG PET CT showed extensive up-take in the
ascending aorta, aortic arch, descending aorta, common iliacs,
femorals, axillary and vertebral arteries in keeping with wide-spread
large vessel involvement.
Results: Due to the disease severity, the failure of previous DMARDs
and steroid related side-effects, we decided to treat her with
intravenous TCZ 8 mg/Kg monthly infusions after obtaining formal
consent.
Immediately after her first infusion, the patient reported excellent
response (100% improvement in global wellbeing) and resolution of
PMR symptoms and headaches with normalisation of her inflammatory
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markers (C-reactive protein decreased from 78 mg/L to 1 mg/L).
Prednisolone dose is currently tapered to 5 mg, with a gradual wean.
Conclusions: We report the successful use of TCZ in a case of
resistant large vessel biopsy positive GCA complicating PMR. There is
an unmet need for better treatment of GCA and PMR due to frequent
relapses adverse events seen with steroid therapy. The pathogenesis
of the conditions suggests that IL-6 is a good target for newer
therapies and our case substantiates this impression. We propose a
multi-centre randomised controlled trial of TCZ in active PMR and
GCA resistant to steroid therapy.
Disclosure statement: The authors have declared no conflicts of
interest.
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Juan Scali4, Moshe Zilberstein5, Emma ‘ Vernon6 and
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Background: The humanised monoclonal antibody tocilizumab (TCZ)
targets the interleukin-6 receptor and is an effective therapy for RA.
Using pooled data from Phase III clinical trials (OPTION, TOWARD,
RADIATE, AMBITION and LITHE) and ongoing long-term extension
studies, the present analysis assessed the longer-term safety of TCZ in
RA patients.
Methods: Patients receiving 1 dose of TCZ in the core trials or their
extension studies (GROWTH95 and GROWTH96) were included in a
pooled analysis of data from initial exposure through to Aug 28 2009.
Results: 4,009 patients received treatment with TCZ; total duration of
observation was 10,994 patient-years (PY) and median (mean) treat-
ment duration was 3.1 (2.7) years. AEs occurred at a rate of 321.1/
100PY (95% CI: 317.8, 324.5) and the SAE rate was 14.6/100PY (95%
CI: 13.9, 15.4); infections were the most frequent AEs (70.7/100PY).
Infections were also the most common SAE, occurring at a rate of 4.5/
100PY (95% CI: 4.1, 4.9). Rates of SAEs and serious infections were
stable over time. The fatality rate was 0.4/100PY (95% CI: 0.3, 0.6).
The rate of malignancies (excluding non-melanoma skin cancer
[NMSC]) was 0.8/100PY; the rate of NMSC was 0.3/100PY. The
overall rate of malignancies did not exceed background rates in the
SEER database and remained stable with continued TCZ therapy. The
rate of gastro-intestinal (GI) perforations (including potential sequelae
from GI perforations, e.g. abscess, strictures) was 2.6/1,000PY (95%
CI: 1.8, 3.8); patients with colonic diverticular perforations accounted
for 59% (17/29) of this total. Preliminary epidemiological data indicate
a higher perforation rate than in the general population, but similar to
that in RA patient populations. Myocardial infarction and stroke
occurred at rates of 0.3 (95% CI: 0.2, 0.4) and 0.2 (95% CI: 0.1, 0.3)
per 100PY, respectively. Rates were stable over time and did not
exceed expected rates in the RA population (myocardial infarction,
0.3-0.8/100PY; stroke, 0.5-0.7/100PY). Eight patients withdrew from
the study for anaphylactic reactions. The rate of withdrawals due to
AEs was 5.4/100PY, with the most common causes being laboratory
abnormalities (1.2/100PY, primarily transaminase elevations), infec-
tions/infestations (1.0/100PY) and neoplasms (benign, malignant,
unspecified, 0.7/100PY).
Conclusions: These results indicate that the longer-term safety profile
of TCZ is consistent with that established in the Phase III studies,
based on stable rates of SAEs, serious infections, malignancies and
cardiovascular events, with continued exposure to TCZ.
Disclosure statement: M.G. has received research grant and
consultancy fees from Roche. A.R. has received consultancy fees
from Abbott Laboratories, Chugai, Essex, Roche, UCB, Inc. and
Wyeth, research grants from Roche and Wyeth Pharmaceuticals, and
is/has been a member of a speakers’ bureau for Roche. A.S. has
received research grants from Amgen, Inc., Bristol-Myers Squibb,
Genentech and Biogen Idec, Inc., Novartis Pharmaceuticals
Corporation and Roche, consultancy fees from Amgen, Inc., Novartis
Pharmaceuticals Corporation and Roche, as is/has been a member of
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TABLE 1. Event rate per 100 PY (95% CI) by 12-month periods
0-12 13-24 25-36 37-48
AEs 416.6 (409.8,
423.4)
296.5 (290.4,
302.7)
271.7 (265.4,
278.0)
250.7 (243.0,
258.5)
SAEs 15.7 (14.4,
17.1)
13.7 (12.4,
15.1)
15.1 (13.6,
16.6)
13.6 (11.8,
15.5)
Serious
infections
4.6 (3.9, 5.4) 3.9 (3.2, 4.6) 5.1 (4.3, 6.1) 4.6 (3.6, 5.8)
Malignancies* 0.9 (0.6, 1.3) 1.1 (0.8, 1.5) 1.3 (0.9, 1.8) 1.4 (0.9, 2.1)
Myocardial
infarction
0.3 (0.1, 0.5) 0.2 (0.1, 0.4) 0.3 (0.1, 0.5) 0.5 (0.2, 1.0)
Stroke 0.3 (0.1, 0.5) 0.1 (0.0, 0.3) 0.2 (0.1, 0.4) 0
* Including NMSC.
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7Rheumatology, Queen’s Hospital, Romford, United Kingdom;
8Neurology, The Queen Elizabeth Hospital Neuroscience Centre,
Birmingham, United Kingdom; 93rd Department of Internal
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Background: Idiopathic inflammatory myopathies (IIM), which in-
cludes dermatomyositis and polymyositis, are conventionally treated
with steroids. Immunosuppressives like ciclosporin and methotrexate
are often used when patients respond incompletely to steroids.
Their efficacies have not been proven in randomised controlled trials
(RCTs). SELAM evaluated their benefits in a placebo-controlled
factorial RCT of two immunosuppressives.
Methods: A 56 week multicentre factorial-design double-blind
placebo-controlled RCT compared steroids alone with added metho-
trexate (15-25 mg weekly), ciclosporin (5 mg/kg/day) and both im-
munosuppressives. Adults with IIM by Bohan and Peter criteria
receiving corticosteroids were enrolled if they had active disease
(4/5 muscle weakness by manual muscle strength testing (MMT) in 2 or
more muscle groups) and functional deficits (one or more activities of
daily living). Patients with inclusion body myositis and muscular
dystrophies were specifically excluded. MMT at 12 months was the
primary outcome. Secondary outcomes comprised a Functional
Rating Scale (FRS), 30 metre walking time (WT), creatine kinase (CK)
and ESR. The primary outcome was analysed using a linear mixed
model. Paired t-tests identified significant changes between baseline
and 12 months in all primary and secondary outcomes.
Results: 58 patients were randomised. They comprised 18 males and
40 females of mean age 50 years: and mean disease duration 2 years.
33 (57%) completed 12 months treatment. Full data was collected in
50 (86%). Analysis of all observed data at 12 months showed no
evidence any immunosuppressive treatment was more effective than
placebo therapy. The mean comparisons of MMT and all secondary
outcomes by active/placebo ciclosporin and methotrexate showed no
significant treatment effects. The combination of both treatments was
also no more effective than placebo (Table 1).
Paired t tests showed the patients improved significantly over 12
months as follows: MMT 15% improvement (p< 0.001), FRS 11%
(p<0.001), WT 13% (p¼0.001) and CK 9%; (p¼ 0.024). Only changes
in CK were different in early (under 3 months) than established (4-220
months) IIM.
Conclusions: SELAM - one of the largest RCTs of immunosup-
pressives in IIM - shows no evidence they give more benefits than
corticosteroids alone. Using immunosuppressives in IIM, in line with
management of other rheumatic diseases, appears questionable. We
need a different therapeutic approach.
Disclosure statement: The authors have declared no conflicts of
interest.
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TABLE 1. Initial and 12 months changes in key observed outcomes by trial group.
Data are presented as mean (S.D.).
Placebo
(n¼15)
Methotrexate
(n¼ 12)
Ciclosporin
(n¼16)
Methotrexate
And
Ciclosporin
(n¼ 15)
Manual Muscle Testing
Baseline 65 (10) 68 (9) 66 (13) 63 (7)
Change 14 (9) 7 (11) 6 (13) 10 (98)
30 Metre Walk
Baseline 31 (21) 35 (23) 37 (24) 35 (20)
Change 6 (16) 8 (10) 6 (13) 9 (12)
Functional Rating Scale
Baseline 35 (4) 32 (4) 32 (5) 32 (6)
Change 2 (4) 3 (3) 3 (5) 4 (6)
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OP10. NEGOTIATING TARGETS FOR
TREATMENT OF RA WITH PATIENTS
Sandra Robinson1 and David Walker1
1Musculoskeletal Research,
Newcastle Upon Tyne Hospitals NHS
Foundation Trust, Newcastle Upon Tyne,
United Kingdom
Background: The new NICE guidance on the management of RA
suggests that a target for treatment is negotiated with patients. This
seems to be a fusion between the ‘‘treat to target’’ studies that have
suggested that multiple treatments are effective and the stated aim of
putting the patient at the centre of their treatment. The details of how
this should be done are not specified. We have previously found that
patients have little understanding of the DAS score and that symptoms
are too subjective to be used in this context. Restriction of a desired
activity was suggested from the previous interviews. We were
interested to explore this by negotiating targets with patients to see
if it was possible in a clinic situation and what patients would specify
as targets.
Methods: 50 consecutive patients with RA were seen in selected
clinics, and were asked to specify a target that could be used to
assess how satisfactory their response to treatment was. They were
asked if they understood what the DAS was and about their
employment status and any impact of their arthritis on paid work.
Results: None of the patients understood the DAS and only one had
heard of it. All but 2 patients were able to express a target in terms of
restricted activity. The negotiation added a total of 1 minute to the
average consultation.
48 expressed a target as either ‘‘maintaining’’ or ‘‘regaining’’ an
activity. Six patients who were unhappy with their condition and
wished to regain an activity, had their treatment increased. The
remaining patients were content with their condition and did not want a
change in therapy.
The targets expressed by the 42 patients wishing to ‘‘maintain’’
their condition were: A distance they could walk 26 (62%); a leisure
activity 6 (14%); a domestic activity 5(12%); remaining at work 4(10%)
and personal care for 1 (2%).
For the 6 wishing to ‘‘regain activities the targets were: A distance
they could walk 2 (33%); a leisure activity 1 (17%) and a domestic
activity 3(50%).
Of 16 who were of working age, 5 were employed. 4 said that
maintaining function to work was their target. 1 identified leisure
activities. None of the patients who had lost their jobs because of
arthritis expressed getting back to work as a target.
Conclusions: Generally patients do not understand the DAS score
and if they are to be used as targets there will need to be huge
educational effort and may not be suitable for some patients. Patients
are able to specify activities that are personal to them and could be
used as targets to indicate whether change of treatment is necessary
or has been successful. Patients who are happy with their condition
express it as maintaining something whereas those unhappy express it
as regain. How realistic and sensitive these targets are will take a
follow-up study.
Work is a target for those in work, but once the work has been lost it
soon ceases to be a target. This suggests that maintaining people in
work is likely to be more successful than trying to get them back to
work later.
Disclosure statement: The authors have declared no conflicts of
interest.
OP11. PHYSICAL INACTIVITY IN
ADULTS WITH RHEUMATIC CONDITIONS
Victoria L. Manning1, Michael Hurley2,
David Scott3 and Lindsay Bearne1
1Division of Health and Social Care Research, King’s College
London, London, United Kingdom; 2Faculty of Health and Social
Care, St Georges University of London, London, United Kingdom;
3School of Medicine, King’s College London, London,
United Kingdom
Background: The National Institute for Health and Clinical Excellence
(NICE) recommend that healthcare professionals (HCP) encourage
people with rheumatic conditions to participate in regular physical
activity (PA) to improve aerobic fitness and general health status (NICE
2008, 2009). Public health guidelines advise that adults with chronic
conditions complete a minimum of 30 minutes (of at least 10 minute
bouts) of moderate intensity PA on five days of the week, or 20 minutes
(of at least 10 minute bouts) of vigorous intensity PA on three days of
the week (ACSM-AHA, 2007). Currently it is not known whether adults
with rheumatic conditions meet these guidelines. This audit investi-
gated whether adults with rheumatic conditions meet public health
guidelines for PA, and whether HCP incorporate PA recommendation
into the management of rheumatic conditions.
Methods: 511 (n¼ 119 males, n¼389 females, n¼ 3 unknown) adults
(44.7% rheumatoid arthritis, 11.3% osteoarthritis, 5.4% psoriatic
arthritis, 4.1% gout, 4.7% systemic lupus erythematosis; 2.3%
ankylosing spondylitis, 4.1% fibromyalgia, 23.4% other (disease
duration (years): mean 7.5, range 0-68)) were recruited from the
rheumatology department of an inner city U.K hospital from July to
October 2010. Participants completed the short format International
Physical Activity Questionnaire (IPAQ), and two closed questions: 1.
Has a doctor or other HCP ever suggested an increase in PA or
exercise to help your arthritis or joint symptoms? 2. Would you like
help from your doctor or health service to become more physically
active? (Answers: yes, no, don’t know/not sure, refused). Descriptive
statistics were completed on all data. Respondents were categorized
as: 1. Meeting PA guidelines (moderate-intensity PA 30 minutes/day
on 5 days/week, or vigorous-intensity PA 20 minutes/day on 3
days/week); 2. Insufficiently active (moderate-intensity PA <30 mi-
nutes/day or <5 days/week, or vigorous-intensity PA <20 minutes/day
or <3 days/week); 3. Inactive (none or <10 minutes moderate or
vigorous-intensity PA/day/activity bout).
Results: 54.5% of respondents met the PA guidelines. The remaining
45.5% of respondents were insufficiently active (18.6%) or inactive
(26.9%). 43.3% of respondents reported that they had been recom-
mended PA by a HCP, yet 48.4% reported that PA had never been
recommended. 7.8% weren’t sure, and 0.4% had refused PA
recommendation. 49.8% of respondents reported that they would
welcome help from their doctor or health service to increase their PA;
34.5% would not, and 15.7% weren’t sure.
Conclusions: Nearly half of respondents did not meet PA guidelines,
the majority of whom were entirely inactive. Many respondents had
never discussed PA with a HCP, yet would welcome help to become
more physically active. Greater awareness of the safety and benefits of
PA may increase activity levels, and recommending PA to meet current
guidelines should form an integral part of the management of adults
with rheumatic conditions.
Disclosure statement: The authors have declared no conflicts of
interest.
OP12. DIFFERENT PHRASING OF
THE PATIENT GLOBAL VISUAL
ANALOGUE SCALE GIVES DIFFERENT
RA DISEASE ACTIVITY SCORE RESULTS
Tracy French1, Sarah Hewlett1,2, John Kirwan1,3 and
Tessa Sanderson1,2
1Rheumatology, University Hospitals Bristol NHS Foundation Trust,
Bristol, United Kingdom; 2Nursing and Midwifery, University of the
West of England, Bristol, United Kingdom; 3Academic Rheumatolgy,
University of Bristol, Bristol, United Kingdom
Background: There are at least 5 different versions of the ‘Patient
Global’ visual analogue scale (PG-VAS) used in the disease activity
score (DAS). The originators of the DAS suggested the PG-VAS can be
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